Studying leftover virus after covid recovery
Part of Infections, Lungs & breathing clinical trials.
This study looks for signs of leftover SARS-CoV-2 virus in people who have fully recovered from COVID-19, including those with ongoing neurological symptoms (like brain fog, fatigue, or nerve pain). It aims to understand why some people have long-lasting symptoms after infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a positive COVID-19 test (PCR or home test confirmed with a blood test) during your infection.
- You have fully recovered from the initial infection (no current active COVID-19).
- You are either healthy now or have ongoing neurological symptoms (like brain fog, fatigue, nerve pain, or dizziness).
- You are not pregnant, breastfeeding, or within a year after giving birth.
- You are willing to travel to the NIH for an extended hospital stay and to share your data and samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses brain scans to understand why people with long COVID feel very tired or have trouble thinking clearly. It could help find new treatments for these symptoms.
This study uses a special PET scan to look at inflammation in the body of people with long COVID (symptoms lasting 3+ months after infection). The goal is to understand why symptoms persist and find better ways to help.
This study looks at how people recover from COVID-19 over time, including those with ongoing symptoms (Long COVID). It involves phone interviews and possibly in-person evaluations to understand long-term effects.
This study uses a special PET scan to look at brain inflammation in people with neurological symptoms after COVID-19. It aims to understand how inflammation might be linked to ongoing problems like brain fog or memory issues.
This study tests whether a drug called pembrolizumab, which helps the immune system, can reduce long-lasting nervous system symptoms from COVID-19 (often called long COVID). It is for people who have had symptoms like fatigue, brain fog, or dizziness for at least 6 months after a mild or moderate COVID infection.
This study looks at what factors may make COVID-19 symptoms or infection effects last after someone has recovered. It also collects certain body samples to better understand why this persistence happens.
Hear when a new PASC Post Acute Sequelae of COVID 19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.